Victoria Ann Merrell, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · Natalie Maclean MD A Professional Corporation
Looking this up.
Hospitals listed: Scripps Memorial Hospital - Encinitas. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Victoria Ann Merrell’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Scripps Memorial Hospital - EncinitasEncinitas, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Scripps Health, which runs 5 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.255, Oct 2024 – Sep 2025
See every measure and the patient survey for Scripps Memorial Hospital - Encinitas
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 4 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.255 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.07 to 1.96) · 1,399 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.64 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (102.82 to 208.07) · 80 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 122 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.6 · 509 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.7 · 637 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 219 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 3,558 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 8,461 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.12 to 0.49) · 8,302 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.72 (1.74 to 5.7) · 1,684 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.14) · 553 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.96 (1.47 to 4.46) · 1,520 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.2 (5.11 to 21.28) · 542 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.42 (1.63 to 9.2) · 545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.14 to 3.05) · 389 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.82) · 5,573 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.6 · 202 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.219 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.439 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.773 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.634 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 748 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -35.2 · 134 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -27.9 · 596 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -30.2 · 693 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 798 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 199 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 172 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.7 to 17) · 345 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.5) · 427 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,383 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$2,788
Medicare paid this office $2,788 for 38 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (30+ min) | 34 | $2,252 | $66 |
Who their Medicare patients are
38 Original Medicare patients in 2024. Average age 75 · Also on Medicaid 0% · Health risk score 0.81. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 53%.
The office billed $7,582, Medicare allowed $4,107 and paid $2,788; for 39 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 38 | 39 | 75 | 0.81 | $7,582 | $2,788 |
| 2023 | 20 | 21 | 75 | 0.71 | $3,897 | $1,376 |
| 2022 | 13 | 15 | 77 | 0.62 | $2,569 | $1,043 |
| 2021 | 124 | 140 | 78 | 1.39 | $21,191 | $10,044 |
| 2020 | 53 | 60 | 75 | 1.27 | $9,705 | $4,061 |
| 2018 | 65 | 88 | 77 | 1.47 | $12,706 | $4,796 |
| 2017 | 156 | 227 | 75 | 1.41 | $31,003 | $11,518 |
| 2016 | 136 | 195 | 76 | 1.40 | $26,277 | $9,803 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| New patient visit (30+ min) | 19 | $1,215 | $64 |
2021: 4 services
| Return visit (30+ min) | 38 | $3,637 | $93 |
| Short return visit (20+ min) | 35 | $2,290 | $64 |
| New patient visit (30+ min) | 14 | $1,155 | $83 |
| New patient visit (15+ min) | 17 | $814 | $48 |
2020: 1 service
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,038 | $80 |
2018: 3 services
| New patient visit (30+ min) | 21 | $1,416 | $67 |
| Short return visit (20+ min) | 21 | $1,158 | $53 |
| Return visit (30+ min) | 12 | $918 | $76 |
2017: 5 services
| Short return visit (20+ min) | 92 | $5,183 | $51 |
| Return visit (30+ min) | 30 | $2,337 | $75 |
| Aspiration and/or injection of fluid from large joint | 25 | $1,434 | $39 |
| New patient visit (30+ min) | 15 | $1,132 | $75 |
| Short return visit | 24 | $863 | $31 |
2016: 5 services
| Short return visit (20+ min) | 76 | $4,046 | $50 |
| Return visit (30+ min) | 32 | $2,573 | $74 |
| Aspiration and/or injection of fluid from large joint | 20 | $986 | $37 |
| New patient visit (30+ min) | 13 | $957 | $74 |
| Short return visit | 23 | $717 | $30 |
Drugs they prescribed that Part D paid
$358,294
Pharmacies billed $358,294 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,147) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
945 generic and fewer than 11 brand-name prescriptions · $358,294 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Taltz | 13 | $88,461 | $6,805 |
| Orencia Clickject | 12 | $65,597 | $5,466 |
| Hydroxychloroquine Sulfate | 177 | $8,737 | $49 |
| Otrexup | 11 | $8,260 | $751 |
| Methotrexate | 204 | $7,499 | $37 |
See all 16 drugs
| Taltz | 13 | $88,461 | $6,805 |
| Orencia Clickject | 12 | $65,597 | $5,466 |
| Hydroxychloroquine Sulfate | 177 | $8,737 | $49 |
| Otrexup | 11 | $8,260 | $751 |
| Methotrexate | 204 | $7,499 | $37 |
| Leucovorin | 210 | $7,001 | $33 |
| Leflunomide | 31 | $2,729 | $88 |
| Cevimeline | 18 | $2,419 | $134 |
| Gabapentin | 69 | $1,896 | $27 |
| Sulfasalazine | 44 | $1,706 | $39 |
| Duloxetine | 49 | $1,341 | $27 |
| Pilocarpine | 20 | $798 | $40 |
| Methotrexate | 31 | $727 | $23 |
| Prednisone | 68 | $679 | $10 |
| Celecoxib | 16 | $335 | $21 |
| Allopurinol | 49 | $307 | $6 |
Year by year
| 2024 | 1,147 | 183 | 0% (0) | None | $358,294 |
| 2023 | 1,280 | 179 | 0% (0) | 25% | $969,488 |
| 2022 | 1,356 | 197 | 0% (0) | None | $759,899 |
| 2021 | 1,331 | 213 | 0% (0) | 18% | $431,504 |
| 2020 | 238 | 98 | 0% (0) | None | $27,681 |
| 2019 | 446 | 114 | 15% (65) | 25% | $191,668 |
| 2018 | 693 | 155 | 31% (216) | 18% | $256,469 |
| 2017 | 619 | 145 | 34% (208) | None | $76,709 |
| 2016 | 645 | 162 | 30% (193) | None | $85,671 |
| 2015 | 770 | 167 | 28% (212) | None | $202,752 |
| 2014 | 827 | 166 | 20% (167) | 20% | $128,591 |
| 2013 | 809 | 159 | 21% (172) | None | $113,898 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Otezla | 37 | $190,986 | $5,162 |
| Cosentyx Sensoready (2 Pens) | 14 | $104,698 | $7,478 |
| Humira(Cf) | 14 | $104,674 | $7,477 |
| Cosentyx (2 Syringes) | 12 | $90,610 | $7,551 |
| Taltz | 12 | $85,360 | $7,113 |
| Enbrel Sureclick | 12 | $81,868 | $6,822 |
| Cimzia | 13 | $67,555 | $5,197 |
| Orencia Clickject | 12 | $62,321 | $5,193 |
| Methotrexate | 225 | $10,061 | $45 |
| Rasuvo | 11 | $9,810 | $892 |
| Hydroxychloroquine Sulfate | 153 | $9,471 | $62 |
| Leucovorin | 207 | $8,102 | $39 |
| Cevimeline | 12 | $4,120 | $343 |
| Sulfasalazine | 48 | $2,673 | $56 |
| Sulfasalazine Dr | 26 | $2,668 | $103 |
| Pilocarpine | 15 | $2,657 | $177 |
| Gabapentin | 59 | $2,071 | $35 |
| Leflunomide | 31 | $1,870 | $60 |
| Duloxetine | 48 | $1,167 | $24 |
| Allopurinol | 51 | $885 | $17 |
| Prednisone | 69 | $848 | $12 |
| Methotrexate | 46 | $758 | $16 |
| Celecoxib | 11 | $300 | $27 |
| Methylprednisolone | 17 | $156 | $9 |
| Folic Acid | 18 | $85 | $5 |
| Insulin | 13 | $68 | $5 |
2022: 27 drugs
| Cosentyx (2 Syringes) | 17 | $113,527 | $6,678 |
| Xeljanz | 15 | $83,591 | $5,573 |
| Otezla | 15 | $77,944 | $5,196 |
| Taltz | 11 | $74,521 | $6,775 |
| Cimzia | 14 | $68,979 | $4,927 |
| Orencia Clickject | 13 | $63,693 | $4,899 |
| Rayos | 12 | $32,296 | $2,691 |
| Hydroxychloroquine Sulfate | 175 | $14,035 | $80 |
| Methotrexate | 231 | $12,615 | $55 |
| Leucovorin | 253 | $10,455 | $41 |
| Rasuvo | 13 | $9,526 | $733 |
| Cevimeline | 20 | $4,072 | $204 |
| Pilocarpine | 20 | $3,813 | $191 |
| Duloxetine | 53 | $3,135 | $59 |
| Gabapentin | 64 | $3,088 | $48 |
| Leflunomide | 16 | $2,974 | $186 |
| Sulfasalazine Dr | 35 | $2,881 | $82 |
| Sulfasalazine | 50 | $2,873 | $57 |
| Allopurinol | 55 | $933 | $17 |
| Methotrexate | 40 | $870 | $22 |
| Celecoxib | 15 | $622 | $41 |
| Prednisone | 49 | $620 | $13 |
| Pregabalin | 14 | $579 | $41 |
| Diclofenac | 20 | $519 | $26 |
| Folic Acid | 19 | $185 | $10 |
| Omeprazole | 16 | $182 | $11 |
| Methylprednisolone | 16 | $155 | $10 |
2021: 23 drugs
| Otezla | 15 | $78,374 | $5,225 |
| Xeljanz | 15 | $78,114 | $5,208 |
| Taltz | 12 | $75,714 | $6,309 |
| Hydroxychloroquine Sulfate | 155 | $15,399 | $99 |
| Methotrexate | 228 | $13,021 | $57 |
| Leucovorin | 236 | $10,782 | $46 |
| Cevimeline | 12 | $5,267 | $439 |
| Pilocarpine | 21 | $3,723 | $177 |
| Leflunomide | 30 | $3,539 | $118 |
| Sulfasalazine Dr | 54 | $3,092 | $57 |
| Sulfasalazine | 59 | $2,915 | $49 |
| Gabapentin | 85 | $2,227 | $26 |
| Duloxetine | 57 | $2,078 | $36 |
| Methotrexate | 50 | $958 | $19 |
| Allopurinol | 43 | $861 | $20 |
| Pregabalin | 16 | $860 | $54 |
| Celecoxib | 13 | $727 | $56 |
| Diclofenac | 24 | $677 | $28 |
| Prednisone | 39 | $464 | $12 |
| Methylprednisolone | 17 | $171 | $10 |
| Folic Acid | 20 | $135 | $7 |
| Alendronate | 11 | $124 | $11 |
| Omeprazole | 11 | $108 | $10 |
2020: 5 drugs
| Methotrexate | 40 | $3,231 | $81 |
| Hydroxychloroquine Sulfate | 21 | $2,755 | $131 |
| Leucovorin | 45 | $1,776 | $39 |
| Sulfasalazine Dr | 21 | $1,523 | $73 |
| Duloxetine | 12 | $1,192 | $99 |
2019: 15 drugs
| Taltz | 14 | $77,659 | $5,547 |
| Forteo | 17 | $58,002 | $3,412 |
| Hydroxychloroquine Sulfate | 24 | $5,894 | $246 |
| Methotrexate | 61 | $3,591 | $59 |
| Sulfasalazine Dr | 30 | $2,926 | $98 |
| Celecoxib | 17 | $1,636 | $96 |
| Gabapentin | 40 | $1,247 | $31 |
| Leucovorin | 34 | $1,222 | $36 |
| Oxycodone-Acetaminophen | 14 | $714 | $51 |
| Hydrocodone-Acetaminophen | 23 | $453 | $20 |
| Allopurinol | 24 | $452 | $19 |
| Prednisone | 21 | $345 | $16 |
| Methylprednisolone | 12 | $154 | $13 |
| Ultra-Fine Mini Pen Needle | 12 | $147 | $12 |
| Tramadol | 11 | $139 | $13 |
2018: 19 drugs
| Otezla | 26 | $85,120 | $3,274 |
| Forteo | 19 | $62,494 | $3,289 |
| Oxycontin | 18 | $7,674 | $426 |
| Hydroxychloroquine Sulfate | 29 | $7,359 | $254 |
| Methotrexate | 39 | $3,276 | $84 |
| Gabapentin | 61 | $3,213 | $53 |
| Leflunomide | 19 | $3,100 | $163 |
| Celecoxib | 40 | $2,585 | $65 |
| Sulfasalazine Dr | 25 | $2,484 | $99 |
| Hydrocodone-Acetaminophen | 78 | $2,076 | $27 |
| Pilocarpine | 15 | $1,898 | $127 |
| Oxycodone-Acetaminophen | 52 | $1,845 | $35 |
| Leucovorin | 35 | $1,218 | $35 |
| Morphine Sulfate Er | 12 | $1,108 | $92 |
| Tramadol | 45 | $656 | $15 |
| Prednisone | 29 | $413 | $14 |
| Methylprednisolone | 28 | $349 | $12 |
| Allopurinol | 12 | $264 | $22 |
| Ultra-Fine Mini Pen Needle | 11 | $133 | $12 |
2017: 18 drugs
| Lyrica | 21 | $13,640 | $650 |
| Oxycontin | 29 | $9,618 | $332 |
| Hydroxychloroquine Sulfate | 34 | $6,949 | $204 |
| Methotrexate | 29 | $2,896 | $100 |
| Duloxetine | 26 | $2,743 | $106 |
| Celecoxib | 23 | $2,128 | $93 |
| Sulfasalazine Dr | 31 | $2,092 | $67 |
| Hydrocodone-Acetaminophen | 77 | $1,759 | $23 |
| Gabapentin | 52 | $1,272 | $24 |
| Oxycodone-Acetaminophen | 52 | $1,241 | $24 |
| Leucovorin | 38 | $1,095 | $29 |
| Morphine Sulfate Er | 13 | $1,022 | $79 |
| Oxycodone | 11 | $523 | $48 |
| Prednisone | 36 | $505 | $14 |
| Methylprednisolone | 12 | $323 | $27 |
| Allopurinol | 13 | $214 | $16 |
| Amitriptyline | 13 | $198 | $15 |
| Tramadol | 23 | $173 | $8 |
2016: 16 drugs
| Hydroxychloroquine Sulfate | 44 | $12,524 | $285 |
| Lyrica | 12 | $6,798 | $567 |
| Oxycontin | 17 | $4,944 | $291 |
| Celecoxib | 22 | $3,462 | $157 |
| Hydrocodone-Acetaminophen | 73 | $2,718 | $37 |
| Methotrexate | 32 | $2,704 | $85 |
| Duloxetine | 28 | $2,678 | $96 |
| Sulfasalazine Dr | 26 | $2,265 | $87 |
| Oxycodone-Acetaminophen | 42 | $1,716 | $41 |
| Leucovorin | 62 | $1,570 | $25 |
| Gabapentin | 51 | $1,395 | $27 |
| Prednisone | 41 | $642 | $16 |
| Omeprazole | 12 | $426 | $36 |
| Methylprednisolone | 19 | $331 | $17 |
| Tramadol | 39 | $257 | $7 |
| Allopurinol | 11 | $251 | $23 |
2015: 21 drugs
| Forteo | 12 | $26,384 | $2,199 |
| Hydroxychloroquine Sulfate | 59 | $15,577 | $264 |
| Lyrica | 13 | $7,128 | $548 |
| Celebrex | 12 | $6,422 | $535 |
| Methotrexate | 51 | $4,845 | $95 |
| Oxycontin | 18 | $3,446 | $191 |
| Celecoxib | 13 | $2,897 | $223 |
| Hydrocodone-Acetaminophen | 84 | $2,509 | $30 |
| Duloxetine | 20 | $2,159 | $108 |
| Morphine Sulfate Er | 18 | $2,049 | $114 |
| Sulfasalazine Dr | 29 | $1,921 | $66 |
| Gabapentin | 59 | $1,544 | $26 |
| Oxycodone-Acetaminophen | 37 | $1,492 | $40 |
| Leucovorin | 59 | $1,221 | $21 |
| Prednisone | 35 | $468 | $13 |
| Omeprazole | 23 | $296 | $13 |
| Methylprednisolone | 17 | $273 | $16 |
| Tramadol | 42 | $227 | $5 |
| Amitriptyline | 13 | $219 | $17 |
| Meloxicam | 13 | $166 | $13 |
| Zolpidem | 15 | $147 | $10 |
2014: 23 drugs
| Forteo | 14 | $21,366 | $1,526 |
| Celebrex | 14 | $7,096 | $507 |
| Methotrexate | 64 | $6,839 | $107 |
| Cevimeline | 14 | $6,673 | $477 |
| Lyrica | 13 | $6,652 | $512 |
| Duloxetine | 20 | $5,747 | $287 |
| Oxycontin | 28 | $4,608 | $165 |
| Pilocarpine | 20 | $2,634 | $132 |
| Oxycodone-Acetaminophen | 41 | $2,351 | $57 |
| Hydroxychloroquine Sulfate | 64 | $1,944 | $30 |
| Leucovorin | 82 | $1,556 | $19 |
| Gabapentin | 48 | $1,343 | $28 |
| Leflunomide | 14 | $1,154 | $82 |
| Morphine Sulfate Er | 18 | $1,127 | $63 |
| Hydrocodone-Acetaminophen | 45 | $1,076 | $24 |
| Sulfasalazine Dr | 18 | $878 | $49 |
| Prednisone | 55 | $836 | $15 |
| Omeprazole | 25 | $494 | $20 |
| Methylprednisolone | 18 | $421 | $23 |
| Sulfazine Ec | 12 | $342 | $28 |
| Tramadol | 27 | $336 | $12 |
| Meloxicam | 13 | $148 | $11 |
| Bd Ultra-Fine Pen Needle | 12 | $120 | $10 |
2013: 22 drugs
| Cymbalta | 11 | $9,169 | $834 |
| Celebrex | 17 | $7,491 | $441 |
| Oxycontin | 26 | $4,995 | $192 |
| Pilocarpine | 41 | $4,545 | $111 |
| Methotrexate | 53 | $4,026 | $76 |
| Leflunomide | 24 | $1,892 | $79 |
| Hydrocodone-Acetaminophen | 45 | $1,732 | $38 |
| Hydroxychloroquine Sulfate | 48 | $1,524 | $32 |
| Gabapentin | 40 | $1,523 | $38 |
| Leucovorin | 75 | $1,512 | $20 |
| Oxycodone Hcl-Acetaminophen | 16 | $847 | $53 |
| Morphine Sulfate Er | 12 | $743 | $62 |
| Oxycodone-Acetaminophen | 24 | $731 | $30 |
| Sulfasalazine Dr | 18 | $690 | $38 |
| Sulfazine Ec | 13 | $637 | $49 |
| Prednisone | 65 | $625 | $10 |
| Methylprednisolone | 23 | $569 | $25 |
| Omeprazole | 19 | $547 | $29 |
| Tramadol | 32 | $357 | $11 |
| Meloxicam | 12 | $139 | $12 |
| Topiramate | 17 | $132 | $8 |
| Zolpidem | 17 | $126 | $7 |
Money from drug and device companies
$3,320 in 2025
| 2025 | 9 | 65 | $1,740 | $3,320 |
| 2024 | 12 | 60 | $2,160 | $3,924 |
| 2023 | 8 | 42 | None | $1,079 |
| 2022 | 8 | 31 | $1,250 | $1,933 |
| 2021 | 8 | 41 | None | $893 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $2,202 | 21 payments
|
| Genzyme | Kevzara | $320 | 4 payments
|
| Abbvie | Rinvoq | $233 | 17 payments
|
| Amgen | Enbrel | $203 | 11 payments
|
| Lilly USA | Taltz | $174 | 8 payments
|
| Novartis Pharmaceuticals | Cosentyx | $113 | 1 payment
|
See all 65 published payments
| Amgen | Meals · 2025-12-19 | Evenity | $17 |
| Amgen | Meals · 2025-11-24 | Otezla | $10 |
| Janssen Biotech | Meals · 2025-11-17 | Tremfya | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-06 | Orencia | $30 |
| Janssen Biotech | Meals · 2025-11-05 | Tremfya | $16 |
| Janssen Biotech | Meals · 2025-11-05 | Tremfya | $3 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-22 | Saphnelo | $25 |
| Janssen Biotech | Meals · 2025-10-20 | Tremfya | $10 |
| Abbvie | Meals · 2025-10-17 | Rinvoq | $5 |
| Lilly USA | Meals · 2025-10-15 | Taltz | $6 |
| Janssen Biotech | Meals · 2025-10-06 | Tremfya | $21 |
| Abbvie | Meals · 2025-09-30 | Rinvoq | $7 |
| Amgen | Meals · 2025-09-15 | Enbrel | $28 |
| Abbvie | Meals · 2025-09-11 | Skyrizi | $6 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $15 |
| Amgen | Meals · 2025-09-08 | Evenity | $25 |
| Lilly USA | Meals · 2025-08-26 | None | $89 |
| Abbvie | Meals · 2025-08-26 | Rinvoq | $4 |
| Abbvie | Meals · 2025-08-26 | Rinvoq | $19 |
| Lilly USA | Meals · 2025-08-17 | Taltz | $30 |
| Janssen Biotech | Meals · 2025-08-13 | Tremfya | $9 |
| Janssen Biotech | Consulting · 2025-08-09 | Tremfya | $1,740 |
| Genzyme | Meals · 2025-08-05 | Kevzara | $25 |
| Janssen Biotech | Meals · 2025-08-04 | Tremfya | $8 |
| Amgen | Meals · 2025-07-28 | Enbrel | $13 |
| Genzyme | Meals · 2025-07-28 | Kevzara | $102 |
| Janssen Biotech | Meals · 2025-07-23 | Tremfya | $115 |
| Janssen Biotech | Meals · 2025-07-14 | Tremfya | $15 |
| Janssen Biotech | Meals · 2025-06-30 | Tremfya | $14 |
| Lilly USA | Meals · 2025-06-25 | Taltz | $10 |
| Janssen Biotech | Meals · 2025-06-17 | Tremfya | $110 |
| Abbvie | Meals · 2025-06-16 | Rinvoq | $18 |
| Amgen | Meals · 2025-06-14 | Evenity | $13 |
| Janssen Biotech | Meals · 2025-06-02 | Tremfya | $16 |
| Abbvie | Meals · 2025-05-20 | Rinvoq | $32 |
| Abbvie | Meals · 2025-05-19 | Rinvoq | $7 |
| Amgen | Meals · 2025-05-19 | Enbrel | $20 |
| Abbvie | Meals · 2025-05-01 | Rinvoq | $9 |
| Lilly USA | Meals · 2025-04-28 | Taltz | $9 |
| Amgen | Meals · 2025-04-22 | Evenity | $21 |
| Janssen Biotech | Meals · 2025-04-21 | Tremfya | $15 |
| Abbvie | Meals · 2025-04-08 | Rinvoq | $13 |
| Amgen | Meals · 2025-04-07 | Krystexxa | $19 |
| Janssen Biotech | Meals · 2025-03-31 | Tremfya | $11 |
| Abbvie | Meals · 2025-03-31 | Skyrizi | $30 |
| Janssen Biotech | Meals · 2025-03-27 | Tremfya | $11 |
| Amgen | Meals · 2025-03-24 | Enbrel | $25 |
| Lilly USA | Meals · 2025-03-19 | Taltz | $13 |
| Abbvie | Meals · 2025-03-17 | Rinvoq | $8 |
| Amgen | Meals · 2025-03-17 | Enbrel | $14 |
| Abbvie | Meals · 2025-03-12 | Rinvoq | $11 |
| Abbvie | Meals · 2025-03-11 | Skyrizi | $26 |
| Janssen Biotech | Meals · 2025-03-10 | Tremfya | $15 |
| Janssen Biotech | Meals · 2025-02-26 | Tremfya | $15 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $12 |
| Abbvie | Meals · 2025-02-24 | Rinvoq | $21 |
| Novartis Pharmaceuticals | Meals · 2025-02-14 | Cosentyx | $113 |
| Genzyme | Meals · 2025-02-12 | Kevzara | $50 |
| Abbvie | Meals · 2025-02-05 | Rinvoq | $9 |
| Lilly USA | Meals · 2025-02-03 | Taltz | $8 |
| Janssen Biotech | Meals · 2025-01-29 | Tremfya | $15 |
| GlaxoSmithKline | Meals · 2025-01-28 | Benlysta | $20 |
| Genzyme | Meals · 2025-01-22 | Kevzara | $143 |
| Abbvie | Meals · 2025-01-08 | Rinvoq | $9 |
| Lilly USA | Meals · 2025-01-06 | Taltz | $10 |
See earlier years (2024, 2023, 2022, 2021)
2024: $3,924
| Janssen Biotech | Tremfya | $2,504 | 15 payments
|
| Amgen | Evenity | $555 | 16 payments
|
| Lilly USA | Taltz | $303 | 11 payments
|
| Abbvie | Rinvoq | $144 | 10 payments
|
| Novartis Pharmaceuticals | Cosentyx | $117 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $100 | 1 payment
|
| Pfizer | None | $67 | 1 payment
|
| Genzyme | Kevzara | $43 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $25 | 1 payment
|
| GlaxoSmithKline | Benlysta | $24 | 1 payment
|
| Genentech USA | Actemra | $24 | 1 payment
|
| Ucb | Bimzelx | $19 | 1 payment
|
2023: $1,079
| Genzyme | Kevzara | $272 | 4 payments
|
| Pfizer | Xeljanz | $197 | 5 payments
|
| Amgen | Enbrel | $195 | 14 payments
|
| Lilly USA | Taltz | $139 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $122 | 1 payment
|
| Abbvie | Rinvoq | $67 | 3 payments
|
| Ucb | Cimzia | $61 | 3 payments
|
| GlaxoSmithKline | Benlysta | $27 | 1 payment
|
2022: $1,933
| Amgen | Otezla | $1,506 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $158 | 3 payments
|
| Pfizer | Xeljanz | $130 | 6 payments
|
| Lilly USA | Taltz | $44 | 2 payments
|
| GlaxoSmithKline | Benlysta | $38 | 2 payments
|
| Janssen Biotech | Remicade | $23 | 1 payment
|
| Ucb | Cimzia | $18 | 1 payment
|
| DePuy Synthes Sales | Orthovisc | $16 | 1 payment
|
2021: $893
| Amgen | Enbrel | $529 | 24 payments
|
| Janssen Biotech | Simponi Aria | $139 | 9 payments
|
| Pfizer | Xeljanz | $110 | 3 payments
|
| AbbVie | Humira | $30 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $29 | 1 payment
|
| Horizon Therapeutics plc | Rayos | $24 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $20 | 1 payment
|
| GlaxoSmithKline | Benlysta | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 95.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1073797395
- Licence
- ID PA-716
- Trained
- University of Washington School of Medicine, 2007
- Group
- Stanford Health Care · Natalie Maclean MD A Professional Corporation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, medical (363AM0700X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-12-21
- NPI last updated
- 2026-04-22
- NPI record certified
- 2026-04-22
This is when the NPI record was last certified, not a medical board exam.